Loading data for IMNN — first visit, this takes a few seconds.
Imunon Inc. (IMNN)
NasdaqCM: IMNN
· Real-Time Price · USD
1.60
+0.00 (0.00%)
At close: Aug 28, 2026, 3:59 PM
1.60
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Imunon Inc. (IMNN) Stock Price, Analysis & Data
0.00% (1D)
| Bid | 1.16 |
| Market Cap | 8.98M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.73M |
| 1.97 | |
| -2.89 | |
| n/a | |
| -0.9 | |
| P/B (ttm) | 3.86 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 2.07 |
| Volume | 82,345 |
| Avg. Volume (20D) | 126,756 |
| Open | 1.60 |
| Previous Close | 1.60 |
| Day's Range | 1.55 - 1.65 |
| 52-Week Range | 1.47 - 6.04 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IMNN
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a C...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 1, 1999
Employees 20
Stock Exchange NasdaqCM
Ticker Symbol IMNN
Website https://imunon.com
Financial Performance
In 2025, Imunon's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -14.5M, a decrease of -22.15%.
Financial StatementsEarnings Surprise
Imunon has released their quarterly earnings on Aug 11, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.54 exceeds estimates by 0.37, with 71.12% YoY growth.
Page 1 of 2